Qian Yang1,1, Shan Kong1,1, Ming Zheng2, Yuelan Hong2, Jing Sun2, Xiaotian Ming2, Yingqiu Gu2, Xianjuan Shen3, Shaoqing Ju1,2. 1. Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China. 2. School of Public Health, Nantong University, Nantong, Jiangsu, China. 3. Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Abstract
BACKGROUND: Long intergenic non-coding RNA (lincRNA) belongs to a special type of RNA that is unable to encode proteins but has been proved to play a role in gene regulation and differentially expressed in various malignant tumors. OBJECTIVE: In this study, we aimed to identify whether lincRNA LINC00173 was differentially expressed in non-small-cell lung cancer (NSCLC) and whether it could serve as a potential diagnostic biomarker. METHODS: The quantification real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect the expression of LINC00173 in serum and cultured cells. For large sample analysis, the lncRNA expression matrix in TCGA database were generated via R software. To evaluate the diagnostic performance of serum LINC00173, the receiver operating characteristic (ROC) curve was used. RESULTS: The qRT-PCR analysis showed that the serum LINC00173 expression level in 108 NSCLC patients was higher than that in 91 healthy donors and 55 patients with benign pulmonary disease (BPD). And the area under the curve (AUC) of serum LINC00173 was 0.809 for the diagnosis of NSCLC (95% CI: 0.750-0.868, p< 0.001), 0.670 for BPD (95% CI: 0.584-0.756, P< 0.001), and 0.730 for small-cell lung cancer (SCLC, 95% CI: 0.636-0.825, P< 0.001). Besides, we established a diagnostic model of combined detection of LINC00173, CEA and Cyfra21-1, and found that combined detection of these indicators significantly improved the diagnostic efficiency. Analysis of the Clinicopathological parameters showed that high LINC00173 expression was correlated with histological typing of tumor, tumor metastasis and serum Cyfra21-1 levels. In addition, serum LINC00173 expression decreased in patients who received chemotherapy and rebound in recurrent NSCLC patients. CONCLUSION: Serum LINC00173 may prove to be a potential non-invasive auxiliary diagnostic biomarker for NSCLC patients.
BACKGROUND: Long intergenic non-coding RNA (lincRNA) belongs to a special type of RNA that is unable to encode proteins but has been proved to play a role in gene regulation and differentially expressed in various malignant tumors. OBJECTIVE: In this study, we aimed to identify whether lincRNA LINC00173 was differentially expressed in non-small-cell lung cancer (NSCLC) and whether it could serve as a potential diagnostic biomarker. METHODS: The quantification real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect the expression of LINC00173 in serum and cultured cells. For large sample analysis, the lncRNA expression matrix in TCGA database were generated via R software. To evaluate the diagnostic performance of serum LINC00173, the receiver operating characteristic (ROC) curve was used. RESULTS: The qRT-PCR analysis showed that the serum LINC00173 expression level in 108 NSCLCpatients was higher than that in 91 healthy donors and 55 patients with benign pulmonary disease (BPD). And the area under the curve (AUC) of serum LINC00173 was 0.809 for the diagnosis of NSCLC (95% CI: 0.750-0.868, p< 0.001), 0.670 for BPD (95% CI: 0.584-0.756, P< 0.001), and 0.730 for small-cell lung cancer (SCLC, 95% CI: 0.636-0.825, P< 0.001). Besides, we established a diagnostic model of combined detection of LINC00173, CEA and Cyfra21-1, and found that combined detection of these indicators significantly improved the diagnostic efficiency. Analysis of the Clinicopathological parameters showed that high LINC00173 expression was correlated with histological typing of tumor, tumor metastasis and serum Cyfra21-1 levels. In addition, serum LINC00173 expression decreased in patients who received chemotherapy and rebound in recurrent NSCLCpatients. CONCLUSION: Serum LINC00173 may prove to be a potential non-invasive auxiliary diagnostic biomarker for NSCLCpatients.
Authors: Didier Ismael May-Hau; Diego Alberto Bárcenas-López; Juan Carlos Núñez-Enríquez; Vilma Carolina Bekker-Méndez; Fredy Omar Beltrán-Anaya; Elva Jiménez-Hernández; Mónica Patricia Ortíz-Maganda; Francisco Xavier Guerra-Castillo; Aurora Medina-Sanson; Janet Flores-Lujano; Jorge Alfonso Martín-Trejo; José Gabriel Peñaloza-González; Martha Margarita Velázquez-Aviña; José Refugio Torres-Nava; Gabriela Alicia Hernández-Echáurregui; Rosa Martha Espinosa-Elizondo; María de Lourdes Gutiérrez-Rivera; Rodrigo Sanchez-Hernandez; María Luisa Pérez-Saldívar; Luz Victoria Flores-Villegas; Laura Elizabeth Merino-Pasaye; David Aldebarán Duarte-Rodríguez; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; Haydeé Rosas-Vargas; Alfredo Hidalgo-Miranda; Juan Manuel Mejía-Aranguré; Silvia Jiménez-Morales Journal: Front Oncol Date: 2022-06-02 Impact factor: 5.738